UPDATE: JMP Securities Raises PT on BioCryst Pharmaceuticals on Potential Game Changer
August 28, 2013 at 11:20 AM EDT
In a report published Wednesday, JMP Securities analyst Liisa A. Bayko reiterated a Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX ), and raised the price target from $5.00 to $8.00. In the report, JMP Securities noted, “Investors see BioCryst's oral kallikrein program as a potential game changer in HAE;